Business Wire

New Report Highlights That the Czech Republic Could Serve as a Model for the EU in Addressing Smoking Prevalence

Share

Ahead of the start of the Czech Presidency of the Council of the EU in July, the think tank Centre for Economic and Market Analysis (CETA) published the comparative study “A new approach towards tobacco legislation: the case for harm reduction in CEE and the EU” at an event in Prague. It presents a new measure, the so-called ‘Harm Reduction Index’ which ranks EU Member States according to their ability to implement the concept of risk reduction.

Yesterday, an event organised by the Czech think tank Centre for Economic and Market Analysis (CETA) brought together medical and addiction experts in Prague to discuss how a tobacco-free generation, where less than 5% of EU-citizens use tobacco, can be achieved by 2040. They concluded that the objectives laid out in Europe’s Beating Cancer Plan cannot be attained under current circumstances and that a revised tobacco control policy based on scientific evidence is needed.

"If the European Commission is serious about its plans to reduce the number of smokers and the impact of smoking, it must start considering the concept of risk reduction in the area of smoking,” Czech National Drug Coordinator Mgr. Jindřich Vobořil highlighted at the event. “The Czech Government has committed itself to this approach in its programme statement for the upcoming Presidency. I will also promote it in relation to the ongoing evaluation of the Tobacco Products Directive, which is an effective policy to achieve a real reduction in the number of smokers of conventional cigarettes,” he added.

"The data show that the abstinence approach is inadequate. The solution for smokers is to switch to less harmful alternatives," agreed Assoc. Ernest Groman, MD, from the Vienna Nicotine Institute. The only European country close to the 5% target is Sweden. According to the experts, the low number of smokers is mainly due to the availability of less harmful alternatives.

Assoc. MUDr. Viktor Mravčík, Ph.D added that,"Theharm reduction approach should be implemented by the European Commission in the context of Europe’s Beating Cancer Plan and the revision of the Tobacco Products Directive.”

"According to the Harm Reduction Index, the Czech Republic ranks second among the countries compared. The Czech government should use the upcoming Presidency to undertake a comprehensive review of tobacco dependence policies based on science rather than emotion,” CETA Research Director Ing. Aleš Rod, Ph. D. and member of the Advisory Board to the Czech Government concluded.

About CETA:

The Centre for Economic and Market Analysis (CETA) is a non-governmental, non-profit organisation that aims to analyse market, socio-economic and political phenomena and highlight their impacts.

The Institute for Rational Addiction Policies is a multidisciplinary association of independent and distinguished experts who are dedicated to research and education in the field of addiction from all perspectives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aleš Rod
ales.rod@eceta.cz

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats28.6.2022 12:00:00 CEST | Press release

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System DNA printer. This success was achieved as part of a contract with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), first announced in January 2021. The partnership leverages the SYNTAX System to produce high-quality DNA primers and probes to rapidly develop qPCR assays for infectious disease detection. Based on these results, the collaboration has been extended to further test EDS primers and probes for qPCR assay development, giving the DGA access to new versions of synthesis and labeling technologies that the company commercially develops. This market’s applications in biodefense are a strategic focus contributing to the sovereign production of biological assays for the French Ministry for the Armed Fo

Aleph Farms Hires Chief of Regulatory Affairs Ahead of Global Commercialization28.6.2022 12:00:00 CEST | Press release

Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced the addition of Yifat Gavriel as Chief of Regulatory Affairs and Quality Assurance. In this position, Gavriel will play a critical role in the introduction of Aleph Farms’ novel products into global markets. The establishment of a regulatory approval process for cultivated meat is underway in many countries around the world, with the Singapore Food Agency the first to approve it as an ingredient in 2020. “Yifat brings valuable expertise to the team, and we are delighted to have her join us at such a critical juncture in our journey to market,” said Didier Toubia, CEO and co-founder of Aleph Farms. “In our work with regulatory agencies around the world, we have seen firsthand how they encourage innovation and have been willing to continue transparent dialogues with us and the wider cultivated meat industry. The next 6-12 months will prove critical as we wo

MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis28.6.2022 11:23:00 CEST | Press release

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with Pouchitis. MH002 is the first, rationally designed, consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical development in Pouchitis. Pouchitis (inflammation of the surgically constructed pouch after colectomy) is the most prominent complication after surgical removal of the large bowel (colectomy) that is performed as a last resort treatment in Ulcerative Colitis (UC). Pouchitis occurs in up to 50% of these patients within 1-2 years after surgery. Disease mechanisms include impaired gut wall barrier function linked to gut microbiome dysbiosis, translocatio

L&T Technology Services Inaugurates Engineering Design Centre in France28.6.2022 10:00:00 CEST | Press release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, inaugurated its Engineering Design Centre (EDC) in Toulouse, France, to initially cater to the new age digital requirements of the global aerospace and defence sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005829/en/ Seen in the picture during the Ribbon Cutting Ceremony (from left to right): Deepanshu Khurana, Embassy of India; Véronique Canceill, Airbus; Amit Chadha, LTTS; Patrice Vassal, Invest in Toulouse; Marie-Eve Rigollet, Airbus (Photo: Business Wire) The EDC will initially focus on developing cutting-edge solutions for the aerospace and defence industries and LTTS will work with major OEMs in the region as an engineering partner. The center will specialize in end-to-end solutions for aerospace design & manufacturing, with a workforce of LTTS engineers having proven expertise in digital e

Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record28.6.2022 09:43:00 CEST | Press release

A Turkish medical team has successfully separated conjoined twins shortly after birth by employing a range of innovative techniques, including virtual simulations and 3D modeling. Carried out at Istanbul’s Acibadem Hospital, the successful procedure set a new world record for the fastest-ever operation of its kind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005307/en/ Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record (Photo: Business Wire) “Thanks to our team of dedicated professionals, we were able to separate the twins in a well-planned surgical procedure that took about nine hours,” Prof. Mehmet Veli Karaaltin, who supervised the operation, says. He is an M.D. specialized in aesthetic, plastic and reconstructive surgery. As a result of the procedure, the twins, who were born conjoined at the breastbone but has two hearts, were both able to survive on their own. Born in Algeria, the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom